Found 15 hodgkin lymphoma trials
A listing of hodgkin lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 53422: An Open-Label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma The Protocol
Phase 1
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
A Phase 3 Randomized Double-Blind Placebo-Controlled Parallel Arm Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
Senza5 CART5 to enhance immunotherapy against T cell non-Hodgkin lymphoma
To determine the safety profile and recommended phase II dose (RP2D) for Senza5 CART5 in participants with CD5+ nodal T cell lymphoma following lymphodepletion with cyclophosphamide and fludarabine. recommended phase II dose of Senza5 CART5 (investigational product) maximum tolerated dose of Senza5 CART5 (investigational product); response rates to investigational therapy …
UPCC 30423: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non- Hodgkin Lymphoma
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
UPCC 35423 Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)
Please refer to Protocol Section 3.1 (Primary Objectives, Endpoints & Hypotheses). Please refer to Protocol Section 3.1 Primary Objectives, Endpoints & Hypotheses. Please refer to Protocol Section 3.2 (Secondary Objectives and Endpoints).
RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY
Phase 2
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
UPCC 43422: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Please refer to Protocol 17-054, Section 2.0 (Objectives and Scientific Aims) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Primary Endpoints) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Secondary Endpoints)
SAGE-Purview HD
Assess magnitude of the baseline differences between participants with early Huntington's Disease & healthy participants with respect to measures of cognitive performance, evaluate effect of SAGE-718 on cognition & functioning outcomes in participants with HD & to evaluate safety & tolerability of SAGE718 in participants with HD, evaluate reliability & …
UPCC 24423: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints).
UPCC 05423 A Phase I, Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leuk
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
1 - 10 of 15
- 1
- 2
